Hillgene
Latest round
- Series A
Last raised
- Apr 2023
Total raised
- Undisclosed
Investors
- 10
About Hillgene
, doing business named as Hillgene, operates as a cell and gene therapy drug solutions provider, focusing on cellular therapy drugs. The company also established two GMP manufacturing sites in Shenzhen and Shanghai. And the North Carolina site in the US is under construction. Its GMP facility covers over 18,000 square meters. Moreover, it submissions 6 IND, and has over 200 prepared cells for clinical use. As of FY2023, the company's cumulative order book exceeds RMB600 million and is 100% cell therapy CDMO (Contract Development & Manufacturing Organization) orders. The company focuses on the field of cellular therapeutics, we have built a plasmid construction platform for cellular drugs, a suspension serum-free virus production platform and a fully enclosed cellular process development platform. Hillgene provides reagent kits for plasmids, mRNA, lentivirus, viruses, antibodies, and, CAR-T. It established technology platforms including nucleic acid, CDMO services platform, lentiviral vectors, immune cells, and stem cells. The company also provides cell CDMO services, lentiviral CDMO services, and plasmid CDMO services. Besides, it also provides testing services and pharmacy quality control research.
Who invested in Hillgene
10 investors across 2 rounds
See all investors in Hillgene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hillgene
Who invested in Hillgene?
Hillgene has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hillgene raised?
Hillgene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Hillgene last raise money?
Hillgene's most recent round on record is a Series A, in Apr 2023.
What does Hillgene do?
, doing business named as Hillgene, operates as a cell and gene therapy drug solutions provider, focusing on cellular therapy drugs.
Where is Hillgene headquartered?
Hillgene is headquartered in Suzhou, China.
Which VCs invest in companies like Hillgene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Hillgene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hillgene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.